Pfizer Inc. (NYSE:PFE) Shares Sold by Gulf International Bank UK Ltd

Key Points

• Gulf International Bank UK Ltd decreased its holdings in Pfizer Inc. by 25.5%, selling 111,144 shares and holding 325,037 shares worth approximately $8.24 million at the end of the quarter.
• Pfizer reported an EPS of $0.78 for its last quarterly results, exceeding analysts' expectations of $0.58, with a revenue of $14.65 billion for the quarter.
• The company declared a quarterly dividend of $0.43, amounting to an annualized yield of 7.0%, scheduled for payment on September 2nd.

Gulf International Bank UK Ltd trimmed its position in Pfizer Inc. (NYSE:PFE - Free Report) by 25.5% during the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 325,037 shares of the biopharmaceutical company's stock after selling 111,144 shares during the period. Gulf International Bank UK Ltd's holdings in Pfizer were worth $8,236,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds have also recently made changes to their positions in PFE. Vanguard Group Inc. grew its position in Pfizer by 0.9% during the 1st quarter. Vanguard Group Inc. now owns 523,165,127 shares of the biopharmaceutical company's stock worth $13,257,004,000 after purchasing an additional 4,629,976 shares during the period. Northern Trust Corp grew its position in Pfizer by 7.7% during the 4th quarter. Northern Trust Corp now owns 58,382,560 shares of the biopharmaceutical company's stock worth $1,548,889,000 after purchasing an additional 4,167,222 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its position in Pfizer by 3.5% during the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 39,402,619 shares of the biopharmaceutical company's stock worth $1,045,351,000 after purchasing an additional 1,333,740 shares during the period. Invesco Ltd. grew its position in Pfizer by 2.8% during the 1st quarter. Invesco Ltd. now owns 30,296,337 shares of the biopharmaceutical company's stock worth $767,709,000 after purchasing an additional 838,198 shares during the period. Finally, Deutsche Bank AG grew its position in Pfizer by 7.0% during the 1st quarter. Deutsche Bank AG now owns 28,239,197 shares of the biopharmaceutical company's stock worth $715,581,000 after purchasing an additional 1,846,436 shares during the period. 68.36% of the stock is owned by institutional investors and hedge funds.

Pfizer Price Performance

PFE traded down $0.05 during trading on Thursday, reaching $25.12. The company's stock had a trading volume of 32,461,964 shares, compared to its average volume of 45,756,129. The company has a quick ratio of 0.85, a current ratio of 1.16 and a debt-to-equity ratio of 0.65. The firm has a fifty day simple moving average of $24.52 and a two-hundred day simple moving average of $24.47. Pfizer Inc. has a 1 year low of $20.92 and a 1 year high of $30.43. The company has a market cap of $142.79 billion, a price-to-earnings ratio of 13.36, a PEG ratio of 0.88 and a beta of 0.52.

Pfizer (NYSE:PFE - Get Free Report) last released its earnings results on Tuesday, August 5th. The biopharmaceutical company reported $0.78 earnings per share for the quarter, topping analysts' consensus estimates of $0.58 by $0.20. Pfizer had a net margin of 16.84% and a return on equity of 21.42%. The business had revenue of $14.65 billion for the quarter, compared to analyst estimates of $13.43 billion. During the same period last year, the company posted $0.60 EPS. The business's revenue was up 10.3% on a year-over-year basis. As a group, analysts anticipate that Pfizer Inc. will post 2.95 EPS for the current year.

Pfizer Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, September 2nd. Shareholders of record on Friday, July 25th will be paid a $0.43 dividend. This represents a $1.72 dividend on an annualized basis and a yield of 6.8%. The ex-dividend date of this dividend is Friday, July 25th. Pfizer's dividend payout ratio (DPR) is 91.49%.

Analysts Set New Price Targets

A number of research firms have recently commented on PFE. Wolfe Research raised their target price on Pfizer from $22.00 to $23.00 and gave the company an "underperform" rating in a research report on Wednesday, April 30th. Redburn Atlantic dropped their target price on Pfizer from $29.00 to $27.00 and set a "neutral" rating on the stock in a research report on Wednesday, April 30th. UBS Group raised their target price on Pfizer from $24.00 to $25.00 and gave the company a "neutral" rating in a research report on Wednesday, April 30th. Jefferies Financial Group raised their target price on Pfizer from $32.00 to $33.00 and gave the company a "buy" rating in a research report on Wednesday, May 21st. Finally, TD Cowen dropped their target price on Pfizer from $32.00 to $28.00 and set a "hold" rating on the stock in a research report on Tuesday, April 22nd. One equities research analyst has rated the stock with a sell rating, eleven have issued a hold rating, five have assigned a buy rating and two have given a strong buy rating to the company. According to data from MarketBeat, the company has an average rating of "Hold" and a consensus price target of $28.12.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.